SHANGHAI, July 27, 2020 /PRNewswire/ -- Aiming to provide
better health management services to lung cancer patients, "Cloud
Enabled Lung Cancer Care by Great Doctors" was officially launched
in Shanghai on July 25, 2020. The lung cancer patient care
program (the "Program"), spearheaded by China Primary Health Care
Foundation and co-hosted by Beijing Life Oasis Public Service
Center, attracted the participation of 20 domestic and
world-renowned lung cancer pharmaceutical and medical equipment
companies. The Program offers diagnostic and treatment services
including science popularization, medication guides, online
consultation, follow-up consultation and clinic visitation support
for lung cancer patients via a full life-cycle doctor-patient
interaction platform. The platform is to be established and
operated by 111, Inc. ("111"), a leading online healthcare company
in China.
The Program adopts the "internet + healthcare" model with the
goals of improving the efficiency of medical service delivery and
the quality of survival of patients through systematic,
professional and personalized multi-dimensional behavioral
intervention for lung cancer patients," said Liu Xiaopeng,
Secretary-General of the Life Oasis Public Service Center of China
Primary Health Care Foundation – a representative of hosts of the
Program.
Prof. Jiang Liyan, Director of
the Pulmonary Tumor Committee of China Medicine Education
Association, said, "The lung cancer patient care program helps
doctors to test and track the medical conditions of patients, which
in turn, facilitates the establishment of a standardized management
database with accumulation of patients' medical information and a
vast array of continuously updated and vetted treatment guidelines
from the deep experience of clinicians in field of lung cancer in
China. The patient management
platform is a good start for China
to set up its own normative lung cancer management model."
According to Chief Innovation Officer Anfeng Guo of 111, lung cancer patients have been
facing challenges in gaining access to timely, professional and
personalized management services such as diagnosis and treatment
during the continuation phase, in particularly when they are at
home. 111 will leverage its online healthcare operational
experience and new technology application to set up an efficient
and one-stop digital service platform for the Program to empower
lung cancer management for the benefits of lung cancer
patients.
Supported by the platform, many patient services have been
migrated from offline to online. Digitalization, visualization and
non-contact are biggest features and advantages.
For patients, the Program removes the inherent limits of time
and space in accessing to professional services, hence achieving
rapid, efficient interaction between patients and attending
physicians. Meanwhile, the virtual visits and consultation during
the pandemic outbreak lowers the risk of infection caused by low
immunity.
For clinicians, gathering data of single-disease cancer patients
in a single digital platform will significantly reduce patient's
management cost, improve service efficiency and accumulate
patients' data to further enhance clinical research. Data
structuring and quantification can help doctors to understand
conditions of patients and assist them in prediction, diagnosis and
treatment.
For pharmaceutical companies, the platform can improve patients'
medication compliance, enhance treatment effectiveness, and
strengthen the competitiveness of products in the treatment
process.
As an online healthcare pioneer and leader, 111 has had an
enormous pool of patients with chronic diseases accumulated over
the course of past ten years. Driven by new technologies like smart
supply chain, cloud solutions, big data and AI, 111 has been
focusing on the upgrade and innovation of its service model and
continuous enhancement of its chromic disease management services.
Participation in the Program is a significant move for 111 to
enhance its single-disease cancer management services and also
marks a key milestone to further enrich its chronic disease
management services.
Dr. Yu Gang, Co-Founder and
Executive Chairman of 111, pointed out that 111 has successfully
launched fully digitalized and smart healthcare management service
that centers on patients with the goals of empowering doctors
through connecting patients and doctors with internet technology.
It is an innovation of 111 in online healthcare and also a new move
for 111 to drive its strategic initiative in drug commercialization
for pharmaceutical companies, especially in cancer drugs,
leveraging on its competitive advantage in smart healthcare supply
chain resources.
Looking into the future, 111 will continue to leverage on its
integrated healthcare platform that combines both offline and
online resources to launch solutions for the omni-channel
commercialization of drugs; further broaden and deepen full
life-cycle management solutions for patients; improve medical
service efficiency and quality of survival of patients, and fulfil
the mission of connecting patients, drugs and medical services with
digital technology.
Ranks as the first in morbidity and mortality among various
kinds of cancers, lung cancer is the "number one killer"
threatening lives and health no matter in China or in the world1. According
to the latest China Malignant Tumor Morbidity and Mortality
Analysis Report released by the National Cancer Center, there were
2.09 million new lung cancer cases worldwide in 2018, of which
Asia accounted for over 50%.
Meanwhile, lung cancer caused 1.76 million deaths globally in 2018,
higher than combined deaths caused by breast cancer, colorectal
cancer and prostatic cancer.
The World Health Organization once estimated that China will have over 1 million new lung cancer
cases a year by 20252. Currently, the five-year survival
rate in China is only
16.1%3. In recent years, with continuous technological
breakthroughs in new treatments, the survival period of lung cancer
patients saw continuous extension and lung cancer turned into a
"controllable chromic disease" from an "incurable disease". It is
foreseeable that lung cancer prevention and treatment will be an
important public health issue with huge market potential in
China in the future.
____________
1. GLOBOCAN 2018 published by
the official journal of American Cancer Society
2. World Cancer Report 2014
by the World Health Organization
3. Public data by the
National Cancer Center
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a Company
dedicated to digitally connecting patients with drugs and
healthcare services in China. The
Company provides hundreds of millions of consumers with better
access to pharmaceutical products and medical services directly
through its online retail pharmacy and indirectly through its
offline pharmacy network. 111 also offers online medical services
through its internet hospital, 1 Clinic, which provides consumers
with cost-effective and convenient online consultation and
electronic prescription services. In addition to providing direct
services to consumers through its online retail pharmacy, 111 also
enables offline pharmacies to better serve their customers.
The Company's online wholesale pharmacy, 1 Drug Mall, serves as a
one-stop shop for pharmacies to source a vast selection of
pharmaceutical products. The Company's New Retail platform, by
integrating the front and back ends of the pharmaceutical supply
chain, has formed a smart supply chain, which transforms the flow
of pharmaceutical products to pharmacies and modernizes how they
serve their customers.
For more information on 111, please visit:
http://ir.111.com.cn/.
For more information, please contact:
111, Inc.
Investor Relations
Email: ir@111.com.cn
111, Inc.
Media Relations
Email: press@111.com.cn
Phone: +86-021-2053 6666 (China)
GCM Strategic Communications
IR Counsel
Email: 111.ir@gcm.international
View original
content:http://www.prnewswire.com/news-releases/111-inc-launched-lung-cancer-patient-care-program-cloud-enabled-lung-cancer-care-by-great-doctors-for-full-life-cycle-management-of-tumor-301100066.html
SOURCE 111, Inc.